Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Archimedes licenses Oramorph for Germany

This article was originally published in Scrip

Executive Summary

The UK firm Archimedes Pharmahas licensed from Molteni Farmaceutici the German rights for Oramorph. Oramorph is the only oral liquid immediate-release morphine sulphate product in patient-friendly unit dose vials available in Germany, and acts quickly to initiate morphine therapy in patients with cancer pain. The product is expected to pave the way for the expected launch of Archimedes’s fentanyl nasal spray, Nasalfent, which is currently in Phase III clinical trials. The German immediate-release morphine market is worth around €17.5 million and is growing at 7% per annum.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts